| Bioactivity | Tozadenant is an adenosine A2A receptor antagonist, with Ki of 11.5 nM on human A2A and 6 nM on rhesus A2A. | ||||||||||||
| Target | Ki: 6 nM (Rhesus A2A), 11.5 nM (Human A2A) | ||||||||||||
| In Vivo | 18F-MNI-444 regional uptake is consistent with A2A receptor distribution in the brain. Selectivity is demonstrated by dose-dependent blocking by tozadenant (1.5, 10.5 mg/kg) and preladenant[1]. | ||||||||||||
| Name | Tozadenant | ||||||||||||
| CAS | 870070-55-6 | ||||||||||||
| Formula | C19H26N4O4S | ||||||||||||
| Molar Mass | 406.50 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Olivier Barret, et al. Adenosine 2A Receptor Occupancy by Tozadenant and Preladenant in Rhesus Monkeys. J Nucl Med. 2014 Oct;55(10):1712-8. |